Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180 Philips makes the scanner a playground to ease children through a scary MRI Hospitals have spent more than $3B on personal protective equipment since COVID-19 began BioNova leapfrogs into the clinic with $200M Sutro blood cancer pact Boston biotech backers quit Dana-Farber board after U-turn on investment policy: report Eli Lilly, Boehringer roll out video game for doctors to highlight cardio-renal-metabolic disease connections Best Buy ramps up focus on home health care by acquiring Current Health Withings goes head-to-head with Apple, nabbing FDA OK for smartwatch to detect afib, sleep apnea CureVac giving up on first COVID mRNA vax, focusing on GSK-partnered 2nd attempt Spinoff or $54B sale? GlaxoSmithKline's consumer health outfit draws buyout interest: report Kaiser Family Foundation: Public not buying pharma's arguments over drug price reforms MindMaze finds its way to $125M for neuro-rehabilitation video game platform Featured Story | By Eric Sagonowsky Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, his company was already in talks for its first M&A deal under the new helmsman, a securities filing shows. read more |
| |
|---|
|
Top Stories By Conor Hale Philips launched a digital coach to help parents and children cope with the stress of the procedure and get out the jitters before having to lie still for a clean image. read more By Dave Muoio Providers' PPE expenses peaked during the second quarter of 2020 due to high demand and increased prices, according to a Premier Inc. analysis. Spending has "steadily declined" since then, but still remains well above pre-pandemic averages. read more By Kyle LaHucik BioNova wants in on Sutro Biopharma's phase 1 antibody-drug conjugate for hematologic cancers and will pay up to $200 million to develop and commercialize the asset in greater China. read more By Nick Paul Taylor Dana-Farber Cancer Institute has reportedly barred trustees from newly investing in biotechs created to license its science, leading to the resignation of board members including a co-founder of C4 Therapeutics. read more By Natalie Missakian The heart, kidneys and endocrine system are interconnected. Yet specialists treating patients with cardiovascular, renal and metabolic diseases often focus only on their areas of expertise. Eli Lilly and Boehringer Ingelheim launched a new construction-themed video game to encourage cross-specialty cooperation—and boost adoption of new treatment guidelines. read more By Heather Landi Best Buy is ramping up its healthcare strategy and its focus on delivering healthcare to people's homes by scooping up Current Health. The consumer electronics retailer plans to combine Current Health’s remote care management platform with its existing health products and services. read more By Andrea Park There’s a new medical-grade smartwatch in town, and it just might give the long-dominant Apple Watch a run for its money. read more By Ben Adams With more than a touch of inevitability, CureVac is abandoning its first mRNA COVID vaccine after dismal results earlier this year, and switching focus to its second mRNA asset with GlaxoSmithKline. read more By Angus Liu As GlaxoSmithKline approaches the end of a two-year journey to spin off its consumer health joint venture with Pfizer, the demerger pathway suddenly looks less certain. Several private equity firms are reportedly sizing up the unit, which could be valued at $54 billion. read more By Robert King A new poll finds that a large swath of the public aren't buying the pharmaceutical industry's arguments against giving Medicare drug price negotiation authority. read more By Andrea Park With the new funding, MindMaze has now achieved the elusive unicorn status, with an estimated valuation of $1.5 billion. read more |
